Vertex Pharmaceuticals has chosen to advance experimental therapies VX-659 and VX-445 into late stage development as part of two different triple combination regimens for people with cystic fibrosis (CF).
My mHealth and LumiraDx Care Solutions have partnered to offer digital self-care to millions of patients in the UK, combining the groups’ expertise in clinical management software and digital technology.
Roche’s balovaptan has picked up a Breakthrough Therapy Designation in the US for its potential as a treatment for people with autism spectrum disorder (ASD), potentially placing the drug on a faster path to market.
AstraZeneca recently unveiled top-line trial data backing use of an experimental triple combination therapy being developed for use with its Aerosphere technology in patients with chronic obstructive pulmonary disease (COPD).
European regulators have approved MSD’s Prevymis for the prevention of cytomegalovirus (CMV) reactivation and disease in prone adults who have received an allogeneic haematopoietic stem cell transplant (HSCT).
A charity survey has highlighted an “urgent need” for earlier diagnosis of kidney cancer, revealing that, in 51 percent of cases, the disease is detected from scans relating to other health conditions.
Santhera's attempt to win approval for Raxone as a treatment for Duchenne Muscular Dystrophy (DMD) in Europe has hit a giant setback after receiving a negative opinion from European Medicines Agency advisors.